Indication

In combination with lazertinib for the first‑line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations.

Medicine details

Medicine name:
amivantamab (Rybrevant)
SMC ID:
SMC2834
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC